Publication

Article

Pharmacy Times

December 2015 Heart Health
Volume81
Issue 12

COPD Linked to Higher Lung Cancer Risk Among Smokers

Although smoking is a well-known risk factor for lung cancer, the results of a recent study indicate that smokers with chronic obstructive pulmonary disease (COPD) face a significantly higher risk of developing lung cancer than smokers without the respiratory condition.

Although smoking is a well-known risk factor for lung cancer, the results of a recent study indicate that smokers with chronic obstructive pulmonary disease (COPD) face a significantly higher risk of developing lung cancer than smokers without the respiratory condition.

The study, published in EBioMedicine, analyzed data from 24 previous studies that enrolled a total of 4346 patients with small cell lung cancer (SCLC), which accounts for 15% to 18% of lung cancers worldwide, and 37,942 individuals without the disease.

After examining the participants’ smoking history, the researchers determined that patients who smoked a pack a day for less than 20 years were 4 times as likely to develop SCLC as nonsmokers, while those who smoked a pack a day for more than 80 years had a nearly 70-fold higher SCLC risk. Additionally, smokers with COPD were 1.86 times more likely to develop SCLC than smokers without COPD, with COPD accounting for 8% of SCLC cases among smokers.

“This work suggests that we need to tease out the mechanisms by which COPD may increase lung cancer risk in smokers and to conduct clinical trials to determine whether treating COPD in former and current smokers lessens that risk,” said senior author David Christiani, MD, in a press release.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com